Prospective Recurrent Pregnancy Loss Registry

NCT05989178 · tracked via the Priya Life Science Canada tracker

Sponsor

University of British Columbia

Phase

Observational

Started

2022-07-12

Last updated

2024-12-13

Condition(s) studied

Recurrent Pregnancy Loss

Investigational drug(s) / intervention(s)

Data Registry

Data Registry: Follow-up questionnaires sent every year for the 5 years following the patient's initial visit.

Study summary

The purpose of this Registry is to prospectively collect data of Recurrent Pregnancy Loss (RPL) patients attending the specialized care centre at the BC Women's Hospital, in order to evaluate investigation practices, treatment options, and outcomes for this patient population over time.

Eligibility

Sex

FEMALE

Min age

15 Years

Max age

49 Years

Healthy volunteers

Inclusion Criteria: • Patients seen at the BC Women's Recurrent Pregnancy Loss Clinic with recurrent pregnancy loss, defined as ≥2 pregnancy losses before 20 weeks of gestation. Exclusion Criteria: • Patients at BC Women's Recurrent Pregnancy Loss Clinic seen for reasons other than recurrent pregnancy loss.

Primary outcome measure(s)

Live Birth — 5 years
Percent of patients with a live birth within 5 years after initial visit at the clinic.

Trial sites (1)

Facility	City	Region	Status
BC Women's Hospital & Health Centre	Vancouver	British Columbia	Recruiting

More University of British Columbia trials in Canada

FIRE-Diet: Food as an Intervention to Reduce the Effects of Woodsmoke Exposure on Respiratory Health Recruiting

Virtual Reality Exposure for Vaginismus: A Replicated Single-Case Design Active, not recruiting

UBC Breakfast Study 2.0 Recruiting

British Columbia Prescriber Feedback Program - Antimicrobial Resistance Starting soon

Intelligent Care Platform - Quasi-Experimental Trial Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05989178 on ClinicalTrials.gov ↗ ← All trials in Canada